Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

HLA-haplotype banking and iPS cells

Nature Biotechnology volume 26, pages 739–740 (2008)Cite this article

To the editor:

The production of induced pluripotent stem (iPS) cell lines from human somatic cells, such as skin fibroblasts, recently reported in your January issue1 and elsewhere2,3,4, opens the exciting new possibility of producing personalized pluripotent stem cell lines from individual patients without using human oocytes or embryos. In addition to circumventing ethical problems associated with human embryonic stem (ES) cells, this new approach could also address immunological rejection associated with cell therapies because iPS cell lines could be created with human leukocyte antigen (HLA)-haplotypes matching those of individual patients. Although such personalized stem cells are possible, the time and cost necessary for the production of clinical-grade iPS cell lines, the production of differentiated cell types for transplantation and the safety validation of all these procedures (including the final cell products for therapy) could limit wide adoption in clinical practice.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Nakagawa, M. et al. Nat. Biotechnol. 26, 101–106 (2008)

    Article  CAS  Google Scholar 

  2. Yu, J. et al. Science 318, 1917–1920 (2007).

    Article  CAS  Google Scholar 

  3. Park, I.-H. et al. Nature 451, 141–146 (2008)

    Article  CAS  Google Scholar 

  4. Takahashi, K. et al. Cell 131, 861–872 (2007).

    Article  CAS  Google Scholar 

  5. Taylor, C. et al. Lancet 366, 2019–2025 (2005).

    Article  Google Scholar 

  6. Nakajima, F., Tokunaga, K. & Nakatsuji, N. Stem Cells 25, 983–985 (2007).

    Article  CAS  Google Scholar 

  7. Revazova, E.S. et al. Cloning Stem Cells 10, 11–24 (2008).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute for Integrated Cell-Material Sciences and Institute for Frontier Medical Sciences, Kyoto University, Kyoto, Japan

    Norio Nakatsuji

  2. Research and Development Department, Central Blood Institute, Japanese Red Cross Society, Tokyo, Japan

    Fumiaki Nakajima

  3. Department of Human Genetics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan

    Katsushi Tokunaga

Authors
  1. Norio Nakatsuji
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fumiaki Nakajima
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Katsushi Tokunaga
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nakatsuji, N., Nakajima, F. & Tokunaga, K. HLA-haplotype banking and iPS cells. Nat Biotechnol 26, 739–740 (2008). https://doi.org/10.1038/nbt0708-739

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0708-739

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing